Table 1.
MMP-3, -1, and -7 SNPs and Endometrial Cancer Risk, evaluated among 1,037 cases and 1,018 controls, The Shanghai Endometrial Cancer Study
| Endometrial Cancer Risk, OR (95% CI) § | |||||||
|---|---|---|---|---|---|---|---|
| Gene, SNP | Region | Alleles 1 | MAF 2 | HWE p-value 3 | AB | BB | p-value |
| MMP-3 | |||||||
| rs645419 | promoter | G/A | 32.6% | 0.573 | 1.1 (0.9–1.3) | 1.0 (0.8–1.4) | 0.628 |
| rs632478 | promoter | C/A | 33.0% | 0.766 | 1.1 (0.9–1.3) | 1.0 (0.8–1.4) | 0.717 |
| rs522616 | promoter | A/G | 36.2% | 0.700 | 1.0 (0.8–1.2) | 1.2 (0.9–1.6) | 0.321 |
| rs679620 | exon 2 | G/A | 32.9% | 0.754 | 1.1 (0.9–1.3) | 1.0 (0.8–1.4) | 0.765 |
| rs650108 | intron 8 | A/G | 40.2% | 0.905 | 1.0 (0.9–1.3) | 1.1 (0.8–1.4) | 0.624 |
| rs655403 | intron 8 | C/T | 7.2% | 0.552 | 1.0 (0.8–1.3) | 1.5 (0.4–5.3) | 0.832 |
| MMP-1 | |||||||
| rs484915 | promoter | A/T | 34.2% | 0.311 | 1.0 (0.8–1.2) | 0.9 (0.7–1.3) | 0.777 |
| rs1155764 | promoter | T/G | 22.0% | 0.765 | 0.9 (0.7–1.0) | 1.1 (0.7–1.7) | 0.397 |
| rs509332 | promoter | A/G | 13.4% | 0.124 | 1.1 (0.9–1.4) | 0.8 (0.4–1.5) | 0.639 |
| rs470206 | promoter | G/A | 13.4% | 0.114 | 1.1 (0.9–1.4) | 0.8 (0.5–1.5) | 0.672 |
| rs2075847 | promoter | T/C | 24.0% | 0.253 | 1.1 (0.9–1.3) | 1.2 (0.8–1.6) | 0.369 |
| rs498186 | promoter | A/C | 44.0% | 0.966 | 1.0 (0.8–1.2) | 0.9 (0.7–1.2) | 0.507 |
| rs475007 | promoter | T/A | 34.0% | 0.702 | 0.9 (0.8–1.1) | 1.1 (0.9–1.5) | 0.626 |
| rs996999 | intron 4 | C/T | 49.1% | 0.291 | 1.1 (0.9–1.3) | 1.0 (0.7–1.2) | 0.731 |
| rs470558 | exon 5 | G/A | 12.4% | 0.642 | 0.9 (0.7–1.1) | 1.0 (0.5–2.2) | 0.421 |
| rs7125062 | intron 6 | C/T | 30.6% | 0.478 | 1.0 (0.8–1.2) | 0.8 (0.6–1.1) | 0.472 |
| rs1938901 | intron 8 | T/C | 42.4% | 0.691 | 1.1 (0.9–1.3) | 1.1 (0.9–1.4) | 0.440 |
| rs2071231 | intron 9 | T/G | 20.4% | 0.607 | 1.1 (0.9–1.3) | 1.2 (0.8–1.8) | 0.173 |
| rs7945189 | 3′ FR * | C/T | 8.8% | 0.250 | 0.9 (0.7–1.1) | 1.3 (0.4–4.3) | 0.411 |
| rs1470504 | 3′ FR * | G/A | 13.9% | 0.663 | 0.9 (0.7–1.1) | 0.9 (0.4–1.7) | 0.328 |
| MMP-7 | |||||||
| rs880197 | promoter | A/T | 38.7% | 0.755 | 0.9 (0.7–1.1) | 0.9 (0.7–1.1) | 0.230 |
| rs17098318 | promoter | G/A | 7.9% | 0.309 | 1.0 (0.8–1.2) | 2.2 (0.7–7.2) | 0.782 |
| rs11568818 | promoter | A/G | 8.0% | 0.281 | 1.0 (0.7–1.2) | 2.0 (0.6–6.5) | 0.970 |
| rs11225307 | intron 3 | A/G | 26.5% | 0.461 | 1.1 (0.9–1.3) | 1.1 (0.8–1.6) | 0.325 |
| rs17352054 | intron 5 | A/C | 12.0% | 0.682 | 1.2 (1.0–1.5) | 1.1 (0.6–2.3) | 0.112 |
| rs495041 | 3′ FR * | C/T | 49.5% | 0.508 | 0.9 (0.8–1.2) | 1.0 (0.8–1.2) | 0.741 |
| rs10895304 | 3′ FR * | A/G | 24.5% | 0.853 | 1.0 (0.8–1.2) | 1.0 (0.7–1.5) | 0.865 |
| rs7935378 | 3′ FR * | T/C | 23.0% | 0.941 | 0.9 (0.8–1.1) | 1.1 (0.7–1.6) | 0.655 |
| rs12184413 | 3′ FR * | C/T | 29.5% | 0.577 | 0.9 (0.8–1.1) | 1.0 (0.7–1.4) | 0.636 |
| rs11225297 | 3′ FR * | A/T | 20.7% | 0.629 | 1.0 (0.8–1.2) | 0.9 (0.5–1.4) | 0.572 |
1
Major and minor alleles as determined by the distribution among SECS controls
2
Minor allele frequency among SECS controls
3
Hardy-Weinberg equilibrium test, p-value among SECS controls
§
Odds Ratio and 95% Confidence Interval for the risk of endometrial cancer, age and education adjusted; AA major allele homozygous, BB minor allele homozygous, AB heterozygous; p-value for trend
*
3′ Flanking region, downstream of the coding region